Surgical Evacuation & Minimally Invasive Surgery in ICH

Surgical and Minimally Invasive Treatment of ICH

Define the Decision Before Choosing the Operation

Ask whether the immediate goal is rescue from herniation, relief of hydrocephalus, hematoma reduction to improve recovery, diagnosis of a structural cause, or a combination. These are different questions. Hemorrhage location, volume, ventricular extension, neurologic trajectory, baseline function, onset, coagulopathy, and patient preferences all matter. Obtain urgent neurosurgical assessment for deterioration, significant mass effect, posterior fossa compression, or hydrocephalus. Do not wait for a named trial criterion when a patient is actively herniating.

Stabilization includes airway and oxygenation, appropriate blood pressure control, urgent anticoagulant reversal when relevant, and treatment of intracranial pressure emergencies. Osmotherapy and other rescue measures can bridge to an operative decision but do not remove a surgically correctable lesion. Conversely, the presence of blood alone does not mandate the same craniotomy for every patient. Use repeat imaging and examination to reassess the plan, including potentially reversible causes of a poor initial examination.

Open Supratentorial Evacuation

STICH and STICH II did not establish a significant overall primary functional benefit from their early open-surgery strategies in the enrolled populations. Their results do not prove that surgery can never help any patient. STICH II focused on selected superficial lobar hemorrhages without IVH and should not be described as a trial of every deep or ventricular hemorrhage. Trial timing, crossover, baseline consciousness, and operative technique affect interpretation.

For many supratentorial ICH presentations, the usefulness of craniotomy for improving functional outcome or mortality is uncertain. In a deteriorating patient, evacuation may be considered as a lifesaving measure. Decompressive craniectomy with or without evacuation may be considered in selected coma, major shift, or refractory pressure, while functional benefit remains uncertain. An uncertain-benefit recommendation is different from a universal class-III no-benefit prohibition. Explain the goal and uncertainty to the surrogate rather than presenting a procedure as assured restoration of independence.

Catheter Evacuation and MISTIE III

MISTIE III studied catheter-based evacuation with low-dose alteplase in selected stable supratentorial ICH, with careful imaging and hemostatic safeguards. The primary intention-to-treat functional endpoint was neutral: mRS 0–3 at one year occurred in approximately 45% versus 41%. It is incorrect to call the trial a positive randomized proof that every hematoma should be reduced below a particular volume.

An exploratory association linked achieving smaller residual hematoma volume, including the protocol goal of at most 15 mL, with better outcomes. Patients who reach that goal may differ in anatomy, technical success, and other prognostic factors. This association supports a hypothesis and attention to procedural quality; it does not establish causality by itself. Do not confuse parenchymal MISTIE treatment with ventricular CLEAR III treatment or transfer drug regimens between them without the proper protocol.

Early Trans-Sulcal Evacuation and ENRICH

ENRICH compared early minimally invasive trans-sulcal evacuation with guideline-based medical care in selected 30–80-mL lobar or anterior basal ganglia hemorrhages treated within 24 hours. The utility-weighted mRS result at 180 days favored surgery overall, and the benefit was driven by the lobar group. Enrollment of anterior basal ganglia cases stopped after an adaptive futility assessment. This limits a blanket claim of benefit for all deep ICH.

The findings support consideration of the studied approach in appropriate patients and experienced centers. They do not establish superiority of every minimally invasive device, every time window, or every hematoma location. Proposed explanations involving tract preservation or injury remain mechanistic interpretations, not proof of why each subgroup result occurred. Discuss procedural bleeding, infection, tissue injury, anesthesia, and the possibility of survival with substantial dependency alongside potential benefit.

Cerebellar Hemorrhage Is a Separate Emergency

The posterior fossa has little reserve for mass effect. Cerebellar blood can obstruct the fourth ventricle, compress the brainstem, and cause rapid deterioration. Under the 2022 AHA/ASA guideline, immediate surgical removal, with or without EVD, is recommended to reduce mortality when there is neurologic deterioration, brainstem compression, hydrocephalus from ventricular obstruction, or cerebellar ICH volume at least 15 mL. The updated volume criterion should not be replaced by a universal three-centimeter-diameter rule. Shape makes diameter and volume noninterchangeable.

An EVD can address hydrocephalus but may be insufficient when the posterior fossa mass continues to compress the brainstem. Avoid uncontrolled drainage and dangerous pressure gradients. Coordinate posterior fossa decompression and CSF diversion according to the lesion and examination rather than calling every EVD placement alone invariably fatal. Cerebellar infarction has its own evidence and should not inherit every hemorrhage indication unchanged.

Review Outcomes and Postoperative Care

After intervention, monitor examination, pressure when indicated, rebleeding, residual clot, hydrocephalus, wound and device complications, and systemic physiology. Repeat imaging and reassess coagulopathy according to the procedure and trajectory. Plan seizure evaluation for unexplained impairment rather than assuming every delay in awakening is sedation. Address mobility, dysphagia, nutrition, thromboprophylaxis, and rehabilitation as the patient stabilizes.

When counseling, distinguish death, mRS categories, utility-weighted outcomes, and independence. mRS 3 includes a need for help, mRS 4 involves inability to walk or attend bodily needs without assistance, and mRS 5 involves severe dependency; none is synonymous with vegetative state. A lower mortality result can coexist with more severely disabled survivors. The patient's values guide how these outcomes inform a decision.

Sources: MISTIE III, ENRICH, and 2022 ICH guideline summary.

Decision Review